RUNX1 and lung cancer: Importantly, by multicolor immunostaining, we confirmed that pharmaceutical systemic inhibition of Runx1 specifically blocked MMT‐driven CAF formation in the lung cancer TME, shown by a dramatic reduction of MMTs (α‐SMA+ F4/80+) in the Ro5‐3335 treated group in vivo (Figure 7D).